-
1
-
-
80855130376
-
Histopathology of gastrointestinal stromal tumor
-
Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol 2011;104:865-73
-
(2011)
J Surg Oncol
, vol.104
, pp. 865-873
-
-
Miettinen, M.1
Lasota, J.2
-
2
-
-
84857502045
-
Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts
-
Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13:265-74
-
(2012)
Lancet Oncol
, vol.13
, pp. 265-274
-
-
Joensuu, H.1
Vehtari, A.2
Riihimaki, J.3
-
3
-
-
0035142836
-
Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
-
Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12
-
(2001)
Virchows Arch
, vol.438
, pp. 1-12
-
-
Miettinen, M.1
Lasota, J.2
-
4
-
-
0036301722
-
Diagnosis of gastrointestinal stromal tumors: A consensus approach
-
Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65
-
(2002)
Hum Pathol
, vol.33
, pp. 459-465
-
-
Fletcher, C.D.1
Berman, J.J.2
Corless, C.3
-
5
-
-
13744263095
-
The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992 to 2000
-
Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162-8
-
Am J Gastroenterol
, vol.2005
, Issue.100
, pp. 162-168
-
-
Tran, T.1
Davila, J.A.2
El-Serag, H.B.3
-
6
-
-
15644363454
-
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
-
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
-
(1998)
Science
, vol.279
, pp. 577-580
-
-
Hirota, S.1
Isozaki, K.2
Moriyama, Y.3
-
7
-
-
0035890740
-
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
-
Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21
-
(2001)
Cancer Res
, vol.61
, pp. 8118-8121
-
-
Rubin, B.P.1
Singer, S.2
Tsao, C.3
-
8
-
-
0020514752
-
Gastric stromal tumors Reappraisal of histogenesis
-
Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983;7:507-19
-
(1983)
Am J Surg Pathol
, vol.7
, pp. 507-519
-
-
Mazur, M.T.1
Clark, H.B.2
-
9
-
-
0036049018
-
Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas
-
Edmonson JH, Marks RS, Buckner JC, MahoneyMR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002;20:605-12
-
(2002)
Cancer Invest
, vol.20
, pp. 605-612
-
-
Edmonson, J.H.1
Marks, R.S.2
Buckner, J.C.3
Mahoney, M.R.4
-
10
-
-
0036305274
-
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
-
Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77
-
(2002)
Hum Pathol
, vol.33
, pp. 466-477
-
-
Dematteo, R.P.1
Heinrich, M.C.2
El-Rifai, W.M.3
Demetri, G.4
-
11
-
-
0035810148
-
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
-
Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6
-
(2001)
N Engl J Med
, vol.344
, pp. 1052-1056
-
-
Joensuu, H.1
Roberts, P.J.2
Sarlomo-Rikala, M.3
-
12
-
-
0037103424
-
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
-
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80
-
(2002)
N Engl J Med
, vol.347
, pp. 472-480
-
-
Demetri, G.D.1
Von Mehren, M.2
Blanke, C.D.3
-
13
-
-
0642368571
-
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
-
Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9
-
(2003)
J Clin Oncol
, vol.21
, pp. 4342-4349
-
-
Heinrich, M.C.1
Corless, C.L.2
Demetri, G.D.3
-
14
-
-
81855226071
-
Gastrointestinal stromal tumours: Origin and molecular oncology
-
Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11:865-78
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 865-878
-
-
Corless, C.L.1
Barnett, C.M.2
Heinrich, M.C.3
-
15
-
-
0242670019
-
Pdgfra activating mutations in gastrointestinal stromal tumors
-
Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10
-
(2003)
Science
, vol.299
, pp. 708-710
-
-
Heinrich, M.C.1
Corless, C.L.2
Duensing, A.3
-
16
-
-
67650837935
-
An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system
-
Woodall CE III, Brock GN, Fan J, et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg 2009;144:670-8
-
(2009)
Arch Surg
, vol.144
, pp. 670-678
-
-
Woodall, C.E.1
Brock, G.N.2
Fan, J.3
-
17
-
-
84867300058
-
Frequencies of kit and pdgfra mutations in the molecgist prospective population-based study differ from those of advanced GISTs
-
Emile JF, Brahimi S, Coindre JM, et al. Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. Med Oncol 2012;29:1765-72
-
(2012)
Med Oncol
, vol.29
, pp. 1765-1772
-
-
Emile, J.F.1
Brahimi, S.2
Coindre, J.M.3
-
18
-
-
84861732669
-
Adjuvant treatment of GIST: Patient selection and treatment strategies
-
Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 2012;9:351-8
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 351-358
-
-
Joensuu, H.1
-
19
-
-
20844433223
-
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial
-
Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34
-
(2004)
Lancet
, vol.364
, pp. 1127-1134
-
-
Verweij, J.1
Casali, P.G.2
Zalcberg, J.3
-
20
-
-
80855156582
-
Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options
-
Caram MV, Schuetze SM. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options. J Surg Oncol 2011;104:888-95
-
(2011)
J Surg Oncol
, vol.104
, pp. 888-895
-
-
Caram, M.V.1
Schuetze, S.M.2
-
21
-
-
56749156604
-
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: Calgb 150105 study by cancer and leukemia group b and southwest oncology group
-
Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7
-
(2008)
J Clin Oncol
, vol.26
, pp. 5360-5367
-
-
Heinrich, M.C.1
Owzar, K.2
Corless, C.L.3
-
22
-
-
33746401591
-
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
-
Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103
-
(2006)
Eur J Cancer
, vol.42
, pp. 1093-1103
-
-
Debiec-Rychter, M.1
Sciot, R.2
Le Cesne, A.3
-
23
-
-
20344393896
-
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
-
Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-90
-
(2005)
Clin Cancer Res
, vol.11
, pp. 4182-4190
-
-
Antonescu, C.R.1
Besmer, P.2
Guo, T.3
-
24
-
-
20844460619
-
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors
-
Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-19
-
(2004)
Cancer Res
, vol.64
, pp. 5913-5919
-
-
Chen, L.L.1
Trent, J.C.2
Wu, E.F.3
-
25
-
-
14944352767
-
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinibresistant mutants
-
Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinibresistant mutants. Gastroenterology 2005;128:270-9
-
(2005)
Gastroenterology
, vol.128
, pp. 270-279
-
-
Debiec-Rychter, M.1
Cools, J.2
Dumez, H.3
-
26
-
-
50249092801
-
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
-
Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008;216:64-74
-
(2008)
J Pathol
, vol.216
, pp. 64-74
-
-
Liegl, B.1
Kepten Le I, C.2
-
27
-
-
33750595859
-
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
-
Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-74
-
(2006)
J Clin Oncol
, vol.24
, pp. 4764-4774
-
-
Heinrich, M.C.1
Corless, C.L.2
Blanke, C.D.3
-
28
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
-
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
-
(2006)
Lancet
, vol.368
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
-
29
-
-
12244301581
-
Vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
-
(2003)
Clin Cancer Res
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
-
30
-
-
0038204144
-
Su11248 is a novel flt3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
OFarrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605
-
(2003)
Blood
, vol.101
, pp. 3597-3605
-
-
Ofarrell, A.M.1
Abrams, T.J.2
Yuen, H.A.3
-
31
-
-
12444297983
-
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
-
Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225-33
-
(2004)
Angiogenesis
, vol.7
, pp. 225-233
-
-
Osusky, K.L.1
Hallahan, D.E.2
Fu, A.3
-
32
-
-
60849113175
-
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
-
Gajiwala KS, Wu JC, Christensen J, et al. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 2009;106:1542-7
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 1542-1547
-
-
Gajiwala, K.S.1
Wu, J.C.2
Christensen, J.3
-
33
-
-
84886592485
-
Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both im and sunitinib (SU): Right study
-
Kang Y-K, Ryu M-H, Ryoo B-Y, et al. Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): right study. ASCO Meet Abstr 2013;31:LBA10502
-
(2013)
ASCO Meet Abstr
, vol.31
-
-
Kang, Y.-K.1
Ryu, M.-H.2
Ryoo, B.-Y.3
-
34
-
-
84864293774
-
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
-
Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23:1680-7
-
(2012)
Ann Oncol
, vol.23
, pp. 1680-1687
-
-
Reichardt, P.1
Blay, J.Y.2
Gelderblom, H.3
-
35
-
-
79959596313
-
Efficacy and safety of motesanib, an oral inhibitor of vegf, pdgf, and kit receptors, in patients with imatinibresistant gastrointestinal stromal tumors
-
Benjamin RS, Schoffski P, Hartmann JT, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinibresistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011;68:69-77
-
(2011)
Cancer Chemother Pharmacol
, vol.68
, pp. 69-77
-
-
Benjamin, R.S.1
Schoffski, P.2
Hartmann, J.T.3
-
36
-
-
79957615693
-
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: Final results of a phase II study
-
Joensuu H, De Braud F, Grignagni G, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011;104:1686-90
-
(2011)
Br J Cancer
, vol.104
, pp. 1686-1690
-
-
Joensuu, H.1
De Braud, F.2
Grignagni, G.3
-
37
-
-
84864408861
-
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: A phase II study of Korean gastrointestinal stromal tumors study group
-
Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012;30:2377-83
-
(2012)
Invest New Drugs
, vol.30
, pp. 2377-2383
-
-
Park, S.H.1
Ryu, M.H.2
Ryoo, B.Y.3
-
38
-
-
84857519572
-
Sorafenib (sor) in patients (pts) with imatinib (im) and sunitinib (su)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial
-
Kindler HL, Campbell NP, Wroblewski K, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial. ASCO Meet Abstr 2011;29:10009
-
(2011)
ASCO Meet Abstr
, vol.29
, pp. 10009
-
-
Kindler, H.L.1
Campbell, N.P.2
Wroblewski, K.3
-
39
-
-
80054681279
-
A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST)
-
Trent JC, Wathen K, von Mehren M, et al. A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). ASCO Meet Abstr 2011;29:10006
-
(2011)
ASCO Meet Abstr
, vol.29
, pp. 10006
-
-
Trent, J.C.1
Wathen, K.2
Von Mehren, M.3
-
40
-
-
77957171405
-
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors 1990-8
-
Schoffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010;21:1990-8
-
(2010)
Ann Oncol
, vol.21
-
-
Schoffski, P.1
Reichardt, P.2
Blay, J.Y.3
-
41
-
-
84893664406
-
-
Available from: www.clinicaltrials.gov
-
-
-
-
42
-
-
79954499886
-
Regorafenib (bay 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
-
Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55
-
(2011)
Int J Cancer
, vol.129
, pp. 245-255
-
-
Wilhelm, S.M.1
Dumas, J.2
Adnane, L.3
-
43
-
-
4944249117
-
Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
-
45
-
-
19744365702
-
A small molecule-kinase interaction map for clinical kinase inhibitors
-
Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36
-
(2005)
Nat Biotechnol
, vol.23
, pp. 329-336
-
-
Fabian, M.A.1
Biggs, W.H.2
Treiber, D.K.3
-
46
-
-
0034648793
-
Vascular-specific growth factors and blood vessel formation
-
Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8
-
(2000)
Nature
, vol.407
, pp. 242-248
-
-
Yancopoulos, G.D.1
Davis, S.2
Gale, N.W.3
-
47
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
-
48
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
49
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
50
-
-
79851482955
-
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors
-
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
-
(2011)
N Engl J Med
, vol.364
, pp. 501-513
-
-
Raymond, E.1
Dahan, L.2
Raoul, J.L.3
-
51
-
-
84860531989
-
A phase i dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors
-
Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18:2658-67
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2658-2667
-
-
Mross, K.1
Frost, A.2
Steinbild, S.3
-
52
-
-
84861459479
-
Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase i study
-
Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012;106:1722-7
-
(2012)
Br J Cancer
, vol.106
, pp. 1722-1727
-
-
Strumberg, D.1
Scheulen, M.E.2
Schultheis, B.3
-
53
-
-
84863698793
-
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial
-
George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012;30:2401-7
-
(2012)
J Clin Oncol
, vol.30
, pp. 2401-2407
-
-
George, S.1
Wang, Q.2
Heinrich, M.C.3
-
54
-
-
84893652763
-
Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: Response based on genotype
-
George S, Feng Y, von Mehren M, et al. Prolonged survival and disease control in the academic phase II trial of regorafenib in GIST: response based on genotype. ASCO Meet Abstr 2013;31:10511
-
(2013)
ASCO Meet Abstr
, vol.31
, pp. 10511
-
-
George, S.1
Feng, Y.2
Von Mehren, M.3
-
55
-
-
84872892692
-
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebocontrolled, phase 3 trial
-
Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet 2013;381:295-302
-
(2013)
Lancet
, vol.381
, pp. 295-302
-
-
Demetri, G.D.1
Reichardt, P.2
Kang, Y.K.3
-
56
-
-
84885178607
-
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
-
Joulain F, Proskorovsky I, Allegra C, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer 2013;109:1735-43
-
(2013)
Br J Cancer
, vol.109
, pp. 1735-1743
-
-
Joulain, F.1
Proskorovsky, I.2
Allegra, C.3
-
57
-
-
84867047384
-
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
-
Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506
-
(2012)
J Clin Oncol
, vol.30
, pp. 3499-3506
-
-
Van Cutsem, E.1
Tabernero, J.2
Lakomy, R.3
-
58
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
59
-
-
49049105525
-
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study
-
Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523-9
-
(2008)
J Clin Oncol
, vol.26
, pp. 3523-3529
-
-
Hochster, H.S.1
Hart, L.L.2
Ramanathan, R.K.3
-
60
-
-
84872921660
-
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial
-
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12
-
(2013)
Lancet
, vol.381
, pp. 303-312
-
-
Grothey, A.1
Van Cutsem, E.2
Sobrero, A.3
-
61
-
-
84893637040
-
-
Available from: www.fda.gov
-
-
-
|